Growth Metrics

Summit Therapeutics (SMMT) Other Working Capital Changes (2017 - 2026)

Summit Therapeutics filings provide 10 years of Other Working Capital Changes readings, the most recent being -$33000.0 for Q1 2026.

  • Quarterly Other Working Capital Changes rose 98.22% to -$33000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $6.7 million through Mar 2026, up 210.43% year-over-year, with the annual reading at $4.9 million for FY2025, 297.37% up from the prior year.
  • Other Working Capital Changes hit -$33000.0 in Q1 2026 for Summit Therapeutics, down from $8.5 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $8.5 million in Q4 2025 and bottomed at -$7.2 million in Q4 2023.
  • Average Other Working Capital Changes over 5 years is -$73000.0, with a median of -$297000.0 recorded in 2022.
  • Peak annual rise in Other Working Capital Changes hit 664.73% in 2025, while the deepest fall reached 4413.95% in 2025.
  • Summit Therapeutics' Other Working Capital Changes stood at $5.0 million in 2022, then crashed by 243.17% to -$7.2 million in 2023, then soared by 78.92% to -$1.5 million in 2024, then soared by 664.73% to $8.5 million in 2025, then crashed by 100.39% to -$33000.0 in 2026.
  • Per Business Quant, the three most recent readings for SMMT's Other Working Capital Changes are -$33000.0 (Q1 2026), $8.5 million (Q4 2025), and -$3.7 million (Q3 2025).